Your time is valuable, so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.Image by OpenClipart-Vectors on Pixabay
Illumina and PacBio called off a $1.2 billion merger after FTC ran interference, saying the pairing could create a monopoly in the next-generation sequencing market. Illumina will now pay PacBio a termination fee of $98 million.
FDA granted JenaValve a breakthrough device designation for pericardial transcatheter aortic valve replacement (TAVR) system, signaling another promising year for the space. The designation is for severe aortic regurgitation (AR) and AR-dominant mixed aortic valve disease, a life-threatening and seriously debilitating condition, in patients at high risk for surgery.
If you're not already familiar with Zap Surgical's radiosurgical robot, now is a good time to change that. The company just raised $81 million to accelerate commercialization of the Zap-X, an integrated robotic software and hardware solution currently FDA-cleared to provide image-guided stereotactic radiosurgery for tumors, lesions and conditions in the brain, head, and neck. The robot's self-shielded design eliminates the need for costly radiation bunkers.